Change from baseline after 3 months of treatment
. | Metformin . | Placebo . | P . |
---|---|---|---|
n | 14 | 13 | — |
Δ SI (× 10−4 min−1 · μU−1 · ml−1) | 2.6 (CI 1.0–4.1) | 2.5 (CI 1.9–2.9) | 0.26 |
Δ HbA1c (%) | –0.3 ± 0.7 | 0.3 ± 0.7* | 0.03 |
Δ fasting glucose (mmol/l) | –0.9 ± 3.8 | –0.5 ± 3.2* | 0.04 |
Δ insulin dose (units · kg−1 · day−1) | –0.14 ± 0.1 | 0.02 ± 0.2* | 0.01 |
Δ BMI (kg/m2) | –0.05 ± 1.0 | 0.2 ± 0.5 | 0.35 |
. | Metformin . | Placebo . | P . |
---|---|---|---|
n | 14 | 13 | — |
Δ SI (× 10−4 min−1 · μU−1 · ml−1) | 2.6 (CI 1.0–4.1) | 2.5 (CI 1.9–2.9) | 0.26 |
Δ HbA1c (%) | –0.3 ± 0.7 | 0.3 ± 0.7* | 0.03 |
Δ fasting glucose (mmol/l) | –0.9 ± 3.8 | –0.5 ± 3.2* | 0.04 |
Δ insulin dose (units · kg−1 · day−1) | –0.14 ± 0.1 | 0.02 ± 0.2* | 0.01 |
Δ BMI (kg/m2) | –0.05 ± 1.0 | 0.2 ± 0.5 | 0.35 |
Data are means ± SD, except for SI, which is expressed as geometric mean and 95% CI.
P < 0.05 vs. metformin group.